Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 IV SK-1401 vs darbepoetin alfa in hemodialysis patients with renal anemia
jRCT2080223470Phase 3Completed
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Mar 2017
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of darbepoetin alfa in anemia of renal disease (2 arms), sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoint: Clinical equivalence of SK-1401 and darbepoetin alfa. Started Mar 2017; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on jRCT2080223470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223470.